Management ChangeOct 30, 2026, 08:01 AM
NextCure, Inc. Chief Medical Officer to Depart Ahead of Merger
AI Summary
NextCure, Inc. announced that the employment of its Chief Medical Officer, Dr. Udayan Guha, will be terminated effective October 31, 2026. This decision is in contemplation of the company's pending merger with Avere Therapeutics, Inc. Dr. Guha will receive severance benefits as per his existing employment agreement, including enhanced benefits related to a change in control, contingent upon the merger's closing. The company expressed gratitude for Dr. Guha's contributions.
Key Highlights
- Dr. Udayan Guha, Chief Medical Officer, to have employment terminated effective October 31, 2026.
- Departure is in contemplation of the pending merger with Avere Therapeutics, Inc.
- Dr. Guha will receive severance benefits consistent with termination without cause, plus enhanced benefits upon closing of the merger.
Price Impact
More from NXTC